Davis Polk advised Gyroscope Therapeutics Limited on the deal. Gyroscope Therapeutics Limited executed its $148 million private placement of Series C preferred shares. The financing was...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here